Shareholder Update: December 2011

In this issue:

Starpharma raises $35m to advance pipeline

Starpharma signs with Ansell for condom coating

Putting a stop to stubborn BV: The VivaGel© solution

Clinical trials for VivaGel© gather pace

M&G invests $20 million

Dendrimers through the eyes of Professor Donald Tomalia

 

Download: Shareholder Update: December 2011 (pdf file, 628kb)

Starpharma's drug delivery program with Lilly advances

Starpharma today announced the advancement of its drug delivery collaboration with US pharmaceutical corporation Eli Lilly and Company.

Starpharma SPP closes heavily oversubscribed; completing $35m financing

Starpharma  today announced that its Share Purchase Plan (SPP) which closed on Wednesday 7 December 2011, is oversubscribed by more than 400%.  The SPP was capped at $3 million, and shareholders have subscribed a total in excess of $12 million.

Herald Sun: Small fry happy to follow the right moves

Herald Sun Journalist John Beveridge takes a close look at why M&G made a significant investment in Starpharma and what it could mean for other buyers: ‘If you see a clever investor grabbing a stake in a company, there is no problem piggy-backing on their research and following them on board.’

 

Go to the article (external link)


Australian Financial Review: Funds pick up beaten down retail

Australian Financial Review Journalist Brendon Lau investigates the activity of fund managers across a number of key stocks: Emerging biotech Starpharma Holdings has also found itself in demand by institutional investors in the wake of its recent capital raising.

The stock could re-rate, just as Mesoblast did, because M&G – one of the largest UK investment funds that is owned by Prudential Group – bought a 6.7 per cent stake in Starpharma.

M&G also became a major shareholder in Mesoblast in December last year and the stock has rallied around 80 per cent since.

Wall Street Journal: UK’s M&G bets on Aussie anti-HIV gel

Wall Street Journal Reporter Gillian Tan investigates M&G’s stake in Starpharma: ‘M&G emerged with a 6.7 per cent stake in the company after participating in Starpharma’s $32m oversubscribed institutional placement which raised funds to –among other things — accelerate the commercialisation of its VivaGel product which will include a New Drug Application filing with the United States’ Food and Drug Administration.’

 

Go to the article (external link)


M&G Substantial Shareholder Notice

M&G has today lodged a substantial shareholder notice with the ASX advising a 6.7% shareholding in Starpharma following their investment of AUD$20 million in the Share Placement announced last week.

Starpharma secures European (EMA) agreement on BV treatment Phase 3

Starpharma today announced that the Phase 3 clinical trial program for VivaGel® bacterial vaginosis (BV) treatment has now also been agreed with the European Medicines Agency (EMA).

Australian Financial Review: Starpharma’s ‘deep portfolio’ attracts investors

Australian Financial Review Journalist Claire Stewart investigates Starpharma’s continued resilience in a difficult market, noting the significance of its $32m capital raising at market price: As market volatility shakes investors’ confidence, the share prices of many research and development-focused companies are suffering as a result of increasing concerns about capital availability and funding issues.

But for Starpharma, a $260 million pharmaceutical company that develops polymer – or dendrimer – nanotechnology, equity has not been an issue.

This week it raised $32 million through a share placement to institutional investors and it will launch a retail share purchase plan to raise an additional $3 million, opening on November 23.

Australian Life Scientist: Starpharma raises $32m

Australian Life Scientist notes the significance of M&G’s investment in Starpharma: ‘Starpharma Holdings (ASX:SPL) has raised $32 million in a placement, and will seek a further $3 million in a SPP, to help fund clinical trials and new product development.’

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.